VERU — Veru Inc · catalysts, narrative & risks

Veru Inc. (NASDAQ: VERU) — Point-in-Time Research Snapshot (as of Oct 30–31, 2026)

Baseline: As of the Oct 30, 2026 close, VERU traded at ~$2.19 (−1.79% on the day), with a market capitalization of ~$37.3M, a 52-week range of $2.05–$7.33, and a negative trailing P/E. Over the trailing 12 months the stock returned roughly −27.2%, though it is up ~2.3% year-to-date [9][15][20][21][22]. The company is a late-stage, revenue-scarce biopharmaceutical firm (Miami, FL) whose core assets are enobosarm (a SARM) and sabizabulin, plus the historical FC2 female condom business [2][15][20].

Recent Catalysts (roughly Aug–Nov 2026)